Published on
May 13, 2020
- 10:30 GMT
Veru Reports Strong Fiscal 2020 Second Quarter Results as Net Revenues Increase 43%, Gross Profit Up 61%
--Strong Clinical Progress in Advanced Prostate Cancer: VERU-111 Demonstrates Safety and Evidence of Antitumor Activity with Durable PSA Declines and Tumor Regression in Phase 1b Study; Phase 2 Study Enrolling; Plan to Meet with FDA as Positive Clinical …
Distribution channels:
Business & Economy, Consumer Goods
...
